Tislelizumab
BGB-A317-309
Phase 3 small_molecule completed
Quick answer
Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer is a Phase 3 program (small_molecule) at BeiGene with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BeiGene
- Indication
- Recurrent or Metastatic Nasopharyngeal Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed